Noble Financial Raises Earnings Estimates for GeoVax Labs

GeoVax Labs Inc. (NASDAQ:GOVX) – Equities research analysts at Noble Financial lifted their Q2 2026 earnings estimates for shares of GeoVax Labs in a report released on Tuesday, May 19th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings per share of ($2.88) for the quarter, up from their prior estimate of ($10.00). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.91) per share. Noble Financial also issued estimates for GeoVax Labs’ Q3 2026 earnings at ($3.28) EPS, Q4 2026 earnings at ($3.87) EPS and FY2026 earnings at ($12.65) EPS.

GOVX has been the subject of a number of other research reports. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX opened at $2.23 on Thursday. The company has a 50 day simple moving average of $1.43 and a 200 day simple moving average of $4.41. The firm has a market cap of $7.74 million, a PE ratio of -0.12 and a beta of 3.36. GeoVax Labs has a 1 year low of $0.96 and a 1 year high of $34.75.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new position in GeoVax Labs during the 3rd quarter worth approximately $253,000. Jane Street Group LLC bought a new position in GeoVax Labs during the 4th quarter worth approximately $99,000. HRT Financial LP bought a new position in GeoVax Labs during the 4th quarter worth approximately $31,000. Renaissance Technologies LLC bought a new position in GeoVax Labs during the 4th quarter worth approximately $104,000. Finally, Hudson Bay Capital Management LP bought a new position in GeoVax Labs during the 3rd quarter worth approximately $47,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.